相似文献
1
The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models.
Cell Rep. 2012 Dec 27;2(6):1492-7. doi: 10.1016/j.celrep.2012.11.001. Epub 2012 Nov 29.
2
SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo.
PLoS One. 2012;7(4):e34805. doi: 10.1371/journal.pone.0034805. Epub 2012 Apr 12.
3
SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease Models.
Cell Chem Biol. 2016 Jul 21;23(7):849-861. doi: 10.1016/j.chembiol.2016.05.015. Epub 2016 Jul 14.
4
The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model.
ChemMedChem. 2015 Jan;10(1):69-82. doi: 10.1002/cmdc.201402431. Epub 2014 Nov 13.
5
SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis.
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7927-32. doi: 10.1073/pnas.1002924107. Epub 2010 Apr 8.
6
Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors.
Eur J Med Chem. 2014 Apr 9;76:414-26. doi: 10.1016/j.ejmech.2014.02.003. Epub 2014 Feb 6.
7
LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease.
J Huntingtons Dis. 2016 Dec 15;5(4):347-355. doi: 10.3233/JHD-160226.
8
The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia.
PLoS One. 2015 Jan 21;10(1):e0116919. doi: 10.1371/journal.pone.0116919. eCollection 2015.
9
Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.
J Biol Chem. 2005 Jan 7;280(1):556-63. doi: 10.1074/jbc.M410210200. Epub 2004 Oct 19.
10
Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease.
J Neurosci. 2017 Mar 8;37(10):2776-2794. doi: 10.1523/JNEUROSCI.2006-14.2016. Epub 2017 Jan 25.
引用本文的文献
1
Lead-Structure-Based Rigidization Approach to Optimize SirReal-Type Sirt2 Inhibitors.
Molecules. 2025 Apr 11;30(8):1728. doi: 10.3390/molecules30081728.
2
Antioxidant and Anti-Inflammatory Defenses in Huntington's Disease: Roles of NRF2 and PGC-1α, and Therapeutic Strategies.
Life (Basel). 2025 Apr 1;15(4):577. doi: 10.3390/life15040577.
3
The Promise of Epigenetic Editing for Treating Brain Disorders.
Subcell Biochem. 2025;108:111-190. doi: 10.1007/978-3-031-75980-2_4.
4
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer.
Semin Cancer Biol. 2024 Nov;106-107:201-216. doi: 10.1016/j.semcancer.2024.10.005. Epub 2024 Oct 28.
5
Crossing epigenetic frontiers: the intersection of novel histone modifications and diseases.
Signal Transduct Target Ther. 2024 Sep 16;9(1):232. doi: 10.1038/s41392-024-01918-w.
6
Activation and inhibition of sirtuins: From bench to bedside.
Med Res Rev. 2025 Mar;45(2):484-560. doi: 10.1002/med.22076. Epub 2024 Aug 31.
7
Roles of Sirtuins in Hearing Protection.
Pharmaceuticals (Basel). 2024 Jul 28;17(8):998. doi: 10.3390/ph17080998.
8
Nicotinamide N-Methyltransferase (NNMT): A New Hope for Treating Aging and Age-Related Conditions.
Metabolites. 2024 Jun 19;14(6):343. doi: 10.3390/metabo14060343.
9
Context-dependent role of sirtuin 2 in inflammation.
Neural Regen Res. 2025 Mar 1;20(3):682-694. doi: 10.4103/NRR.NRR-D-23-02063. Epub 2024 May 13.
10
Current Trends in Sirtuin Activator and Inhibitor Development.
Molecules. 2024 Mar 6;29(5):1185. doi: 10.3390/molecules29051185.
本文引用的文献
1
Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems.
Hum Mol Genet. 2012 Dec 15;21(24):5280-93. doi: 10.1093/hmg/dds379. Epub 2012 Sep 10.
2
Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
Neurobiol Dis. 2012 May;46(2):351-61. doi: 10.1016/j.nbd.2012.01.016.
3
SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo.
PLoS One. 2012;7(4):e34805. doi: 10.1371/journal.pone.0034805. Epub 2012 Apr 12.
4
3-(N-arylsulfamoyl)benzamides, inhibitors of human sirtuin type 2 (SIRT2).
Bioorg Med Chem Lett. 2012 Apr 15;22(8):2789-93. doi: 10.1016/j.bmcl.2012.02.089. Epub 2012 Mar 3.
5
Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease.
PLoS One. 2012;7(2):e31080. doi: 10.1371/journal.pone.0031080. Epub 2012 Feb 8.
6
Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-3/atypical protein kinase C (aPKC) signaling.
Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):E952-61. doi: 10.1073/pnas.1104969108. Epub 2011 Sep 26.
7
The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS.
Hum Mol Genet. 2011 Oct 15;20(20):3986-96. doi: 10.1093/hmg/ddr326. Epub 2011 Jul 26.
8
Sirt2 is a novel in vivo downstream target of Nkx2.2 and enhances oligodendroglial cell differentiation.
J Mol Cell Biol. 2011 Dec;3(6):351-9. doi: 10.1093/jmcb/mjr009. Epub 2011 Jun 13.
9
A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase.
ACS Chem Biol. 2011 Jun 17;6(6):540-6. doi: 10.1021/cb100376q. Epub 2011 Mar 9.
10
Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington Disease.
PLoS Curr. 2010 Dec 29;2:RRN1205. doi: 10.1371/currents.RRN1205.
Zotero 插件